Year: 2025

Participants who lost 24% total body weight (>50 lbs.) on GLP-1 drugs maintained stable weight 6 months after GLP-1 discontinuation and single Revita treatment 1.5% mean weight change observed with Revita (n=17); published third-party studies after GLP-1 withdrawal alone have shown ~10% weight regain at similar time points Upcoming randomized 6-month REMAIN-1 Midpoint Cohort data expected in January 2026; topline 6-month Pivotal Cohort data and potential PMA filing anticipated in H2 2026 BURLINGTON, Mass., Dec. 02, 2025 (GLOBE NEWSWIRE) — Fractyl Health, Inc. (Nasdaq: GUTS) (the Company or Fractyl), a metabolic therapeutics company focused on pioneering pattern-breaking approaches that treat root causes of obesity and type 2 diabetes (T2D), today announced positive 6-month results from its open-label REVEAL-1 Cohort. The REVEAL-1...

NEW YORK, Dec. 02, 2025 (GLOBE NEWSWIRE) — Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company developing small molecule medicines for brain disorders with significant unmet need, today announced the appointment of Petra Kaufmann, M.D., M.S., F.A.A.N., as Chief Medical Officer. Dr. Kaufmann joins Ovid’s leadership team with responsibility for guiding clinical, medical, and regulatory strategy as the Company progresses a clinical pipeline of potential best- and first-in-class therapeutic candidates for conditions and symptoms driven by neuronal imbalance. Dr. Kaufmann brings extensive experience developing CNS therapeutics from first-in-human studies through to global regulatory approval. The foundation for her expert drug development perspectives began from her early career as a practicing neurologist who treated...

Outcome of conditional license awards has zero impact on Company’s financial performance, outlook or strategy Company believes that its operating capabilities and infrastructure are well suited to support a viable industry in Texas MARFA, Texas, Dec. 02, 2025 (GLOBE NEWSWIRE) — Village Farms International, Inc. (“Village Farms” or the “Company”) (NASDAQ: VFF) today reaffirmed its commitment to the Texas cannabis industry after receiving notice that it was not awarded a conditional medical license as part of the Phase I license awards granted by the Texas Department of Public Safety (DPS) on December 1, 2025. The Company is not yet aware how its application was scored by DPS, but plans to review the licensing process and scoring methodologies with advisors as more information becomes available. The Company’s application will be...

MISSISSAUGA, Ontario, Dec. 02, 2025 (GLOBE NEWSWIRE) — Next Hydrogen Solutions Inc. (TSXV: NXH, OTC: NXHSF) (“Next Hydrogen” or the “Company“), announces that it has changed its auditor from KPMG LLP (“Former Auditor“) to MNP LLP (“Successor Auditor“). The Former Auditor resigned at the request of the Company effective November 30, 2025, and the board of directors of the Company appointed the Successor Auditor as the Company’s auditor effective December 1, 2025, until the next Annual General Meeting of the Company. There were no modified opinions expressed in the Former Auditor’s audit reports for the relevant period, being the two most recently completed financial years of the Company ended December 31, 2024, and 2023 and any period subsequent to the most recently completed...

Vancouver, British Columbia, Dec. 02, 2025 (GLOBE NEWSWIRE) — NevGold Corp. (“NevGold” or the “Company”) (TSXV:NAU) (OTCQX:NAUFF) (Frankfurt:5E50) is pleased to announce further positive high-grade oxide antimony drill results from surface at the newly discovered antimony-gold “Bullet Zone” at its Limousine Butte Project (the “Project”, “Limo Butte”) in Nevada. The Bullet Zone was discovered in the 2025 drill program with step-out drilling testing NevGold’s new geology model at the Project. The Bullet Zone discovery significantly expands the gold-antimony mineralization footprint at the Resurrection Ridge target, which NevGold is advancing to an initial gold-antimony Mineral Resource Estimate (“MRE”). Aerial Drone Footage of 2025 Drilling & Bullet Zone Discovery (Click Here): Key HighlightsHighest-grade antimony (“Antimony”,...

Reductions in airway hyperresponsiveness and suppressed eosinophilic response at both 6 weeks and 12 weeks observed after a single 180mg dose of Briquilimab in the ETESIAN Study Preliminary data from ETESIAN study supports further development of briquilimab in asthma Jasper also announces completion of internal BEACON study investigation noting no deviations or issues with drug product utilized Jasper to host conference call and webinar today at 8:00 a.m. ET REDWOOD CITY, Calif., Dec. 02, 2025 (GLOBE NEWSWIRE) — Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting KIT (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, reported positive...

TOKYO, Dec. 02, 2025 (GLOBE NEWSWIRE) — CTW Cayman (Nasdaq: CTW) (“CTW” or “the Company”), a leading game platform company providing global access to web-based games through its flagship HTML5 platform, G123.jp, today announced that its subsidiary CTW Inc. has officially launched Crayon Shinchan: My Sugoroku Great Strategy, a video game based on the classic traditional Japanese sugoroku board game and the main characters from the popular Japanese manga Crayon Shinchan. Players can immediately enjoy the game on any mobile, PC, or tablet device at G123.jp, which offers free browser games without the need to register or download any game-specific app. Crayon Shinchan: My Sugoroku Great Strategy follows the mischievous main character Shinchan and his friends at Futaba Kindergarten who have decided to make their own sugoroku game with...

Vilnius, Lithuania, Dec. 02, 2025 (GLOBE NEWSWIRE) — As at the end of November 2025, the net asset value (NAV) of SUTNTIB AB Tewox increased to EUR 46,043,930, compared to the previously determined NAV of EUR 44,897,707 at the end of October 2025. The share price increased to EUR 1.0999, from EUR 1.0725 at the end of October 2025. The pro-forma internal rate of return (IRR) increased to 3.72%, compared to previously announced IRR of 3.09% at the end of October 2025. Contact person for further information: Paulius Nevinskas Manager of the Investment Company paulius.nevinskas@lordslb.lt https://lordslb.lt/tewox_bonds/

New award expands Gilat Defense’s portfolio of advanced capabilities PETAH TIKVA, Israel, Dec. 02, 2025 (GLOBE NEWSWIRE) — Gilat Satellite Networks Ltd. (NASDAQ: GILT, TASE: GILT), a worldwide leader in satellite networking technology, solutions, and services, announced today that Gilat DataPath has been selected to deliver a customized Earth Observation Solution. The order, valued at approximately $10 million, will be delivered within the next 12 months. This award reflects the continued expansion of Gilat Defense’s portfolio of specialized capabilities beyond satellite communications and into the earth observation and geospatial insights domain. The tailored solution leverages satellites equipped with various sensors to provide real-time data for intelligence, surveillance, reconnaissance, and situational awareness. The capability...

SOUTH SAN FRANCISCO, Calif., Dec. 02, 2025 (GLOBE NEWSWIRE) — Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat autoimmune diseases, today announced its participation in the Evercore 8th Annual Healthcare Conference on Thursday in Miami. Evercore 8th Annual Healthcare ConferenceDecember 4, 202510:50 a.m. ET – fireside chat A simultaneous webcast of the event will be available on the Investors section of Nkarta’s website, and a replay will be archived on the website for approximately 90 days. About NkartaNkarta is a clinical-stage biotechnology company advancing the development of allogeneic, off-the-shelf natural killer (NK) cell therapies for autoimmune diseases. By combining its cell expansion and cryopreservation platform with proprietary...